Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort

This publication has 31 references indexed in Scilit:

• Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study
  Oncology and Therapy, 2025
• Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
  European Journal of Cancer, 2024
• ESMO Guidance for Reporting Oncology real-World evidence (GROW)
  Annals of Oncology, 2023
• Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
  JAMA Oncology, 2022
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  Annals of Oncology, 2022
• Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis
  Cancer Treatment Reviews, 2022
• The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients
  Cancer Epidemiology, 2021
• Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review
  Clinical Gastroenterology and Hepatology, 2020
• Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
  JAMA Network Open, 2020
• Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
  JAMA Oncology, 2018